Dexter J. Wiseman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dexter J. Wiseman has a total of 259 co-authors. Here are the top co-authors by number of shared publications:
Andrew I. Ritchie
National Heart and Lung Institute, Imperial College London, London, United Kingdom
5 shared publicationsGavin C. Donaldson
National Heart and Lung Institute, Imperial College London, London, United Kingdom
4 shared publicationsJames P. Allinson
National Heart and Lung Institute, Imperial College London, London, United Kingdom
4 shared publicationsFaisal Kamal
National Heart and Lung Institute, Imperial College London, London, United Kingdom
3 shared publicationsG.C. Donaldson
National Heart and Lung Institute, Imperial College London, London, United Kingdom
3 shared publicationsJ.A. Wedzicha
National Heart and Lung Institute, Imperial College London, London, United Kingdom
3 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (12) , 3411-3430
Clinical Burden of Disease and Demographics in Older Adults Hospitalized with RSV Infection in England: A Retrospective Cohort Study
- 6 October 2026
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (12) , 3411-3430
Open AccessClinical Burden of Disease and Demographics in Older Adults Hospitalized with RSV Infection in England: A Retrospective Cohort Study
- Open Access
Clinical burden of disease and demographics in older adults hospitalised with RSV infection in England: A retrospective cohort study
Introduction: Respiratory syncytial virus (RSV) causes significant disease in older and comorbid adults. Current UK vaccination recommendations restrict eligibility to adults ≥75-years, 65-74-years with chronic respiratory disease or immunosuppression, and those in care homes, but evidence on clinical burden in adults <75-years with comorbidities is limited. This study assessed patient characteristics, healthcare resource utilisation (HCRU), and mortality in adults hospitalised with RSV in England. Methods: Population-based retrospective cohort study using linked Clinical Practice Research Datalink Aurum and Hospital Episode Statistics. Adults ≥60-years hospitalised with RSV between October 2014-March 2019 were included. RSV episodes defined as 90-days post diagnosis. Case definitions were created using diagnosis codes related to confirmed RSV (RSV-specific) or acute lower respiratory tract infection where other causative pathogens were excluded (RSV-possible). All-cause HCRU (hospitalisations, critical care admissions, outpatient attendance, primary care consultations, and prescriptions) and case fatality rates were assessed. Results were stratified by age (60-74 and ≥75-years), case definitions (RSV-specific, RSV-possible) and comorbidity profiles (chronic respiratory disease, immunocompromised, cardiovascular disease). Results: A total of 97,712 hospitalised episodes in those aged ≥60-years were included in the analysis, where 785 (0.8%) were RSV-specific cases (n=338 aged 60-74-years, n=447 aged ≥75-years). In RSV-specific cases, median (IQR) cumulative length of stay (LoS) for those ≥75-years was 10.00 (6.00-22.00) days which was equivalent to or lower than each comorbidity sub-group in those aged 60-74-years, with longest LoS in those immunocompromised (11.50 [7.00-26.00] days). Critical care admissions were more often observed across comorbidity stratifications (13.85%-22.34%) compared to those ≥75-years (5.03%). All-cause and RSV-related case fatality rates for RSV-specific cases were highest among those ≥75-years (all-cause: 19.3%; RSV-related: 10.3%). Conclusion: HCRU within RSV episodes in those aged 60-74-years across comorbidity profiles was equal to or greater compared to those aged ≥75-years. These findings highlight the need to prioritise consideration of comorbidity groups that could benefit from RSV vaccination. Key summary points: Why carry out this study?: • There is growing evidence on the burden of disease of RSV, however there is still a question around whether everyone at risk of severe outcomes are covered by the UK vaccination programme. • There is a paucity in evidence on the clinical burden of RSV in adults <75-years, especially in those with comorbidities including cardiovascular risk factors. Granular HCRU and morality outcomes are required to inform policy decisions on RSV vaccination strategies in these groups. • This study aimed to quantify the clinical burden of RSV in adults ≥60-years in England, stratified by comorbidity profile and descriptively compare to those previously eligible for the RSV-vaccine programme in England (aged ≥75-years, and in those in adult care homes). What was learned from the study?: • The study found that the clinical burden of RSV in secondary care in adults aged 60-74-years across all comorbidities stratifications, is equivalent to or exceeds the burden of those aged ≥75-years.
Open AccessClinical burden of disease and demographics in older adults hospitalised with RSV infection in England: A retrospective cohort study
Introduction: Respiratory syncytial virus (RSV) causes significant disease in older and comorbid adults. Current UK vaccination recommendations restrict eligibility to adults ≥75-years, 65-74-years with chronic respiratory disease or immunosuppression, and those in care homes, but evidence on clinical burden in adults <75-years with comorbidities is limited. This study assessed patient characteristics, healthcare resource utilisation (HCRU), and mortality in adults hospitalised with RSV in England. Methods: Population-based retrospective cohort study using linked Clinical Practice Research Datalink Aurum and Hospital Episode Statistics. Adults ≥60-years hospitalised with RSV between October 2014-March 2019 were included. RSV episodes defined as 90-days post diagnosis. Case definitions were created using diagnosis codes related to confirmed RSV (RSV-specific) or acute lower respiratory tract infection where other causative pathogens were excluded (RSV-possible). All-cause HCRU (hospitalisations, critical care admissions, outpatient attendance, primary care consultations, and prescriptions) and case fatality rates were assessed. Results were stratified by age (60-74 and ≥75-years), case definitions (RSV-specific, RSV-possible) and comorbidity profiles (chronic respiratory disease, immunocompromised, cardiovascular disease). Results: A total of 97,712 hospitalised episodes in those aged ≥60-years were included in the analysis, where 785 (0.8%) were RSV-specific cases (n=338 aged 60-74-years, n=447 aged ≥75-years). In RSV-specific cases, median (IQR) cumulative length of stay (LoS) for those ≥75-years was 10.00 (6.00-22.00) days which was equivalent to or lower than each comorbidity sub-group in those aged 60-74-years, with longest LoS in those immunocompromised (11.50 [7.00-26.00] days). Critical care admissions were more often observed across comorbidity stratifications (13.85%-22.34%) compared to those ≥75-years (5.03%). All-cause and RSV-related case fatality rates for RSV-specific cases were highest among those ≥75-years (all-cause: 19.3%; RSV-related: 10.3%). Conclusion: HCRU within RSV episodes in those aged 60-74-years across comorbidity profiles was equal to or greater compared to those aged ≥75-years. These findings highlight the need to prioritise consideration of comorbidity groups that could benefit from RSV vaccination. Key summary points: Why carry out this study?: • There is growing evidence on the burden of disease of RSV, however there is still a question around whether everyone at risk of severe outcomes are covered by the UK vaccination programme. • There is a paucity in evidence on the clinical burden of RSV in adults <75-years, especially in those with comorbidities including cardiovascular risk factors. Granular HCRU and morality outcomes are required to inform policy decisions on RSV vaccination strategies in these groups. • This study aimed to quantify the clinical burden of RSV in adults ≥60-years in England, stratified by comorbidity profile and descriptively compare to those previously eligible for the RSV-vaccine programme in England (aged ≥75-years, and in those in adult care homes). What was learned from the study?: • The study found that the clinical burden of RSV in secondary care in adults aged 60-74-years across all comorbidities stratifications, is equivalent to or exceeds the burden of those aged ≥75-years.
- Open Access
Understanding risk of poor outcomes in adults hospitalised with respiratory syncytial virus infection: evidence from a multicentre UK cohort
Background: Respiratory syncytial virus (RSV) causes substantial winter pressure on adult services. In the UK, RSV vaccination currently targets adults aged ≥75 years and care home residents; it remains uncertain whether this age criterion alone meaningfully discriminates risk of poor outcome among adults hospitalised with RSV. Methods: We pooled three UK hospital cohorts (one prospective, two retrospective) of adults admitted with acute respiratory infection (ARI) and PCR-confirmed RSV. The primary outcome was intensive care unit/high dependency unit (ICU/HDU) admission or all-cause mortality within 60 days. Prespecified predictors (age, sex and comorbidities) entered a least absolute shrinkage and selection operator (LASSO) penalised logistic regression; selected variables were refitted using standard logistic regression. Discrimination, calibration and decision-analytic performance were assessed using 1000-bootstrap internal validation and decision-curve analysis. Results: Among 334 adults, 37 (11.1%) experienced the primary outcome. An age-only rule mirroring current UK vaccine age-eligibility (≥75 years) demonstrated only modest discrimination (optimism-adjusted area under the receiver operating characteristic curve (AUC) 0.58, 95% CI 0.48 to 0.65) and a compressed distribution of predicted risks. A four-predictor model—including age, COPD, active/previous cancer and dementia—achieved higher discrimination AUC (0.77 (0.69 to 0.85)), a wider spread of predicted risks and the greatest net benefit across clinically plausible escalation thresholds (5–20%). Conclusions: In adults hospitalised with RSV-associated ARI, simple age-based heuristics—including the UK ≥75-year threshold—showed only modest ability to discriminate risk of ICU/HDU admission/60-day mortality once hospitalised. Comorbidity-inclusive approaches may provide more informative hospital-level risk stratification and warrant evaluation in future RSV vaccine-effectiveness and outcome studies. Any application requires external validation, more systematic RSV testing and comparison with physiology-based scores in larger, vaccinated cohorts.
Open AccessUnderstanding risk of poor outcomes in adults hospitalised with respiratory syncytial virus infection: evidence from a multicentre UK cohort
Background: Respiratory syncytial virus (RSV) causes substantial winter pressure on adult services. In the UK, RSV vaccination currently targets adults aged ≥75 years and care home residents; it remains uncertain whether this age criterion alone meaningfully discriminates risk of poor outcome among adults hospitalised with RSV. Methods: We pooled three UK hospital cohorts (one prospective, two retrospective) of adults admitted with acute respiratory infection (ARI) and PCR-confirmed RSV. The primary outcome was intensive care unit/high dependency unit (ICU/HDU) admission or all-cause mortality within 60 days. Prespecified predictors (age, sex and comorbidities) entered a least absolute shrinkage and selection operator (LASSO) penalised logistic regression; selected variables were refitted using standard logistic regression. Discrimination, calibration and decision-analytic performance were assessed using 1000-bootstrap internal validation and decision-curve analysis. Results: Among 334 adults, 37 (11.1%) experienced the primary outcome. An age-only rule mirroring current UK vaccine age-eligibility (≥75 years) demonstrated only modest discrimination (optimism-adjusted area under the receiver operating characteristic curve (AUC) 0.58, 95% CI 0.48 to 0.65) and a compressed distribution of predicted risks. A four-predictor model—including age, COPD, active/previous cancer and dementia—achieved higher discrimination AUC (0.77 (0.69 to 0.85)), a wider spread of predicted risks and the greatest net benefit across clinically plausible escalation thresholds (5–20%). Conclusions: In adults hospitalised with RSV-associated ARI, simple age-based heuristics—including the UK ≥75-year threshold—showed only modest ability to discriminate risk of ICU/HDU admission/60-day mortality once hospitalised. Comorbidity-inclusive approaches may provide more informative hospital-level risk stratification and warrant evaluation in future RSV vaccine-effectiveness and outcome studies. Any application requires external validation, more systematic RSV testing and comparison with physiology-based scores in larger, vaccinated cohorts.
- 1 June 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (6) , 946-956
Prevalence and Clinical Correlates of Radiologically Detected Coronary Artery Disease in Chronic Obstructive Pulmonary Disease: A Cross-Sectional Observational Study
Rationale: Unrecognized coronary artery disease (CAD) may contribute to adverse outcomes in chronic obstructive pulmonary disease (COPD). Improved identification of at-risk groups could inform better preventive care. Objectives: We aimed to evaluate the burden and relationships of radiologically detectable CAD in COPD, establish the frequency of occult disease, and examine potential cardiovascular screening methods. Methods: Using computed tomography (CT) coronary angiography, we prospectively evaluated CAD in 50 patients with COPD compared with age- and sex-matched controls. In those with COPD, the relationship of CAD to cardiac symptoms (chest pain, dyspnea), functional capacity (6-minute-walk distance), exacerbations, and inflammation was assessed. The performance of screening tests (cardiovascular risk scores, biomarkers, and thoracic CT–derived coronary artery calcium score) were evaluated using receiver operating characteristic curves. Measurements and Main Results: CAD was present in 88% of patients with COPD (42% had obstructive [⩾50% stenosis of any vessel] and 28% severely obstructive [⩾70%] disease). Rates of obstructive (OR, 3.1; 95% CI, 1.1–8.9; P = 0.037) and severely obstructive CAD (OR, 10.1; 95% CI, 1.9–52.7; P = 0.006) were higher in those with COPD than in controls. In the COPD group, those with CAD had greater functional impairments but not greater dyspnea scores, and 75% reported no chest pain or prior ischemic heart disease. CAD was more extensive in those with increased systemic inflammation (fibrinogen, C-reactive protein, and leukocyte and neutrophil counts), bronchial wall thickening, and sputum bacterial growth but bore no relation to exacerbation frequency. The thoracic CT–derived coronary artery calcium score was an effective screening tool, with areas under the curve of 0.98 (95% CI, 0.95–1.00) for CAD and 0.89 (95% CI, 0.79–1.00) for obstructive CAD. Conclusions: CT coronary angiography–detected CAD is common in patients with COPD but correlates poorly with symptoms and conventional risk scores. Radiological screening with standard (non ECG-gated) CT of the thorax might improve detection and outcome in this patient group.
- 1 June 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (6) , 946-956
Prevalence and Clinical Correlates of Radiologically Detected Coronary Artery Disease in Chronic Obstructive Pulmonary Disease: A Cross-Sectional Observational Study
Rationale: Unrecognized coronary artery disease (CAD) may contribute to adverse outcomes in chronic obstructive pulmonary disease (COPD). Improved identification of at-risk groups could inform better preventive care. Objectives: We aimed to evaluate the burden and relationships of radiologically detectable CAD in COPD, establish the frequency of occult disease, and examine potential cardiovascular screening methods. Methods: Using computed tomography (CT) coronary angiography, we prospectively evaluated CAD in 50 patients with COPD compared with age- and sex-matched controls. In those with COPD, the relationship of CAD to cardiac symptoms (chest pain, dyspnea), functional capacity (6-minute-walk distance), exacerbations, and inflammation was assessed. The performance of screening tests (cardiovascular risk scores, biomarkers, and thoracic CT–derived coronary artery calcium score) were evaluated using receiver operating characteristic curves. Measurements and Main Results: CAD was present in 88% of patients with COPD (42% had obstructive [⩾50% stenosis of any vessel] and 28% severely obstructive [⩾70%] disease). Rates of obstructive (OR, 3.1; 95% CI, 1.1–8.9; P = 0.037) and severely obstructive CAD (OR, 10.1; 95% CI, 1.9–52.7; P = 0.006) were higher in those with COPD than in controls. In the COPD group, those with CAD had greater functional impairments but not greater dyspnea scores, and 75% reported no chest pain or prior ischemic heart disease. CAD was more extensive in those with increased systemic inflammation (fibrinogen, C-reactive protein, and leukocyte and neutrophil counts), bronchial wall thickening, and sputum bacterial growth but bore no relation to exacerbation frequency. The thoracic CT–derived coronary artery calcium score was an effective screening tool, with areas under the curve of 0.98 (95% CI, 0.95–1.00) for CAD and 0.89 (95% CI, 0.79–1.00) for obstructive CAD. Conclusions: CT coronary angiography–detected CAD is common in patients with COPD but correlates poorly with symptoms and conventional risk scores. Radiological screening with standard (non ECG-gated) CT of the thorax might improve detection and outcome in this patient group.
- 1 May 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (5) , 803-813
Select Airway Specialized Proresolving Mediators Are Associated with Recovery from Nonviral Chronic Obstructive Pulmonary Disease Exacerbations
Rationale: Recovery from chronic obstructive pulmonary disease (COPD) exacerbations is heterogeneous and has a profound impact on disease trajectories. Resolution of airway inflammation is an active process that may be driven by specialized proresolving mediators (SPMs). Objectives: We sought to characterize the temporal change in SPMs in the sputum of patients with COPD during exacerbations, their association with exacerbation triggers, and exacerbation recovery. Methods: Participants were recruited from the London COPD Exacerbation Cohort between January 11, 2016, and April 30, 2018. Participants were reviewed at baseline, exacerbation onset, 1 week, 2 weeks, and 6 weeks during their exacerbation recovery. Sputum collection, nasopharyngeal swabs, phlebotomy, quality-of-life questionnaires, and spirometry were performed at each visit. SPMs were measured in sputum by liquid chromatography–tandem mass spectrometry. Respiratory viruses were measured by quantitative PCR and bacteria by microbiological culture. Measurements and Main Results: There were 68 exacerbations during the study period. Median time to symptomatic recovery was 21 days for viral exacerbations, compared with 13 days in nonviral exacerbations (P < 0.001). There was a significant increase in resolvin D1 (RvD1) at exacerbation onset in bacterial exacerbations but not in viral exacerbations. Lower levels of RvD1 were associated with prolonged respiratory symptoms during the 1-week and 2-week recovery time points. Exogenous RvD1 significantly reduced IL-6 and CXCL8 response to rhinovirus infection in COPD bronchial epithelial cells. Conclusions: There is a dynamic temporal change in airway SPMs during COPD exacerbations. Reduced levels of RvD1 were associated with prolonged respiratory symptoms. SPMs may be a potential therapeutic approach to promote exacerbation recovery.
- 1 May 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (5) , 803-813
Select Airway Specialized Proresolving Mediators Are Associated with Recovery from Nonviral Chronic Obstructive Pulmonary Disease Exacerbations
Rationale: Recovery from chronic obstructive pulmonary disease (COPD) exacerbations is heterogeneous and has a profound impact on disease trajectories. Resolution of airway inflammation is an active process that may be driven by specialized proresolving mediators (SPMs). Objectives: We sought to characterize the temporal change in SPMs in the sputum of patients with COPD during exacerbations, their association with exacerbation triggers, and exacerbation recovery. Methods: Participants were recruited from the London COPD Exacerbation Cohort between January 11, 2016, and April 30, 2018. Participants were reviewed at baseline, exacerbation onset, 1 week, 2 weeks, and 6 weeks during their exacerbation recovery. Sputum collection, nasopharyngeal swabs, phlebotomy, quality-of-life questionnaires, and spirometry were performed at each visit. SPMs were measured in sputum by liquid chromatography–tandem mass spectrometry. Respiratory viruses were measured by quantitative PCR and bacteria by microbiological culture. Measurements and Main Results: There were 68 exacerbations during the study period. Median time to symptomatic recovery was 21 days for viral exacerbations, compared with 13 days in nonviral exacerbations (P < 0.001). There was a significant increase in resolvin D1 (RvD1) at exacerbation onset in bacterial exacerbations but not in viral exacerbations. Lower levels of RvD1 were associated with prolonged respiratory symptoms during the 1-week and 2-week recovery time points. Exogenous RvD1 significantly reduced IL-6 and CXCL8 response to rhinovirus infection in COPD bronchial epithelial cells. Conclusions: There is a dynamic temporal change in airway SPMs during COPD exacerbations. Reduced levels of RvD1 were associated with prolonged respiratory symptoms. SPMs may be a potential therapeutic approach to promote exacerbation recovery.
- Open Access
- 15 October 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 210 (8) , 994-1001
Respiratory Syncytial Virus–related Community Chronic Obstructive Pulmonary Disease Exacerbations and Novel Diagnostics: A Binational Prospective Cohort Study
Rationale: Respiratory syncytial virus (RSV) is a common global respiratory virus that is increasingly recognized as a major pathogen in frail older adults and as a cause of chronic obstructive pulmonary disease (COPD) exacerbations. There is no single test for RSV in adults that has acceptable diagnostic accuracy. Trials of RSV vaccines have recently shown excellent safety and efficacy against RSV in older adults; defining the frequency of RSV-related community infections and COPD exacerbations is important for vaccine deployment decisions. Objectives: This prospective study aimed to establish the frequency of outpatient-managed RSV-related exacerbations of COPD in two well-characterized patient cohorts using a combination of diagnostic methods. Methods: Participants were recruited at specialist clinics in London, United Kingdom, and Groningen, the Netherlands, beginning in 2017 and observed for three consecutive RSV seasons, during exacerbations, and at least twice yearly. RSV infections were detected by RT-PCR and serologic testing. Measurements and Main Results: A total of 377 patients with COPD attended 1,999 clinic visits and reported 310 exacerbations. There were 27 RSV-related exacerbations (8.7% of the total); of these, seven were detected only by PCR, 16 only by serology, and four by both methods. Increases in RSV-specific Nucleoprotein antibody were as sensitive as those in the antibody to Pre-Fusion or Post-Fusion for serodiagnosis of RSV-related exacerbations. Conclusions: RSV is associated with 8.7% of outpatient-managed COPD exacerbations in this study. Antibodies to RSV Nucleoprotein may have diagnostic value and are potentially important in a vaccinated population. The introduction of vaccines that prevent RSV is expected to benefit patients with COPD.
- 15 October 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 210 (8) , 994-1001
Open AccessRespiratory Syncytial Virus–related Community Chronic Obstructive Pulmonary Disease Exacerbations and Novel Diagnostics: A Binational Prospective Cohort Study
Rationale: Respiratory syncytial virus (RSV) is a common global respiratory virus that is increasingly recognized as a major pathogen in frail older adults and as a cause of chronic obstructive pulmonary disease (COPD) exacerbations. There is no single test for RSV in adults that has acceptable diagnostic accuracy. Trials of RSV vaccines have recently shown excellent safety and efficacy against RSV in older adults; defining the frequency of RSV-related community infections and COPD exacerbations is important for vaccine deployment decisions. Objectives: This prospective study aimed to establish the frequency of outpatient-managed RSV-related exacerbations of COPD in two well-characterized patient cohorts using a combination of diagnostic methods. Methods: Participants were recruited at specialist clinics in London, United Kingdom, and Groningen, the Netherlands, beginning in 2017 and observed for three consecutive RSV seasons, during exacerbations, and at least twice yearly. RSV infections were detected by RT-PCR and serologic testing. Measurements and Main Results: A total of 377 patients with COPD attended 1,999 clinic visits and reported 310 exacerbations. There were 27 RSV-related exacerbations (8.7% of the total); of these, seven were detected only by PCR, 16 only by serology, and four by both methods. Increases in RSV-specific Nucleoprotein antibody were as sensitive as those in the antibody to Pre-Fusion or Post-Fusion for serodiagnosis of RSV-related exacerbations. Conclusions: RSV is associated with 8.7% of outpatient-managed COPD exacerbations in this study. Antibodies to RSV Nucleoprotein may have diagnostic value and are potentially important in a vaccinated population. The introduction of vaccines that prevent RSV is expected to benefit patients with COPD.
- Open Access
- 30 November 2023
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (6)
Using an electronic diary and wristband accelerometer to detect exacerbations and activity levels in COPD: a feasibility study
Background: Early and accurate identification of acute exacerbations of COPD may lead to earlier treatment and prevent hospital admission. Electronic diaries have been developed for symptom monitoring and accelerometers to monitor activity. However, it is unclear whether this technology is usable in the COPD population. This study aimed to assess the feasibility of an electronic diary (eDiary) for symptom reporting using the MoreCare app and activity monitoring with the Garmin Vivofit 2 in COPD.Methods: Participants were recruited from the London COPD Cohort. Participants were provided a Garmin Vivofit 2 activity monitor and an android tablet with the MoreCare app for a period of 3 months.Results: 25 COPD patients were recruited (mean±sdage 70.8±7.1 years, forced expiratory volume in 1 s (FEV1) 49.8±14.8% predicted). Age, gender, disease severity and exacerbation frequency had no impact on eDiary compliance. There was a moderate positive correlation between median daily very active minutes and FEV1% pred (ρ=0.62, p=0.005). Daily step counts decreased during the initial 7 days of exacerbation and recovery compared to a pre-exacerbation baseline. A decision-tree model identified change in sputum colour, change in step count, severity of cold, exacerbation history and use of rescue medication as the most important predictors of acute exacerbations of COPD in this cohort.Conclusions: Symptom and activity monitoring using digital technology is feasible in COPD. Further large-scale digital health studies are needed to assess whether eDiaries can be used to identify patients at risk of exacerbation and guide early intervention.
- 30 November 2023
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (6)
Open AccessUsing an electronic diary and wristband accelerometer to detect exacerbations and activity levels in COPD: a feasibility study
Background: Early and accurate identification of acute exacerbations of COPD may lead to earlier treatment and prevent hospital admission. Electronic diaries have been developed for symptom monitoring and accelerometers to monitor activity. However, it is unclear whether this technology is usable in the COPD population. This study aimed to assess the feasibility of an electronic diary (eDiary) for symptom reporting using the MoreCare app and activity monitoring with the Garmin Vivofit 2 in COPD.Methods: Participants were recruited from the London COPD Cohort. Participants were provided a Garmin Vivofit 2 activity monitor and an android tablet with the MoreCare app for a period of 3 months.Results: 25 COPD patients were recruited (mean±sdage 70.8±7.1 years, forced expiratory volume in 1 s (FEV1) 49.8±14.8% predicted). Age, gender, disease severity and exacerbation frequency had no impact on eDiary compliance. There was a moderate positive correlation between median daily very active minutes and FEV1% pred (ρ=0.62, p=0.005). Daily step counts decreased during the initial 7 days of exacerbation and recovery compared to a pre-exacerbation baseline. A decision-tree model identified change in sputum colour, change in step count, severity of cold, exacerbation history and use of rescue medication as the most important predictors of acute exacerbations of COPD in this cohort.Conclusions: Symptom and activity monitoring using digital technology is feasible in COPD. Further large-scale digital health studies are needed to assess whether eDiaries can be used to identify patients at risk of exacerbation and guide early intervention.
- Open Access
- 14 December 2022
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 11 (5) , 415-424
Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care
- 14 December 2022
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 11 (5) , 415-424
Open AccessFavipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care
- 1 November 2021
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 204 (9) , 1075-1085
Virus-induced Volatile Organic Compounds Are Detectable in Exhaled Breath during Pulmonary Infection
Rationale: Chronic obstructive pulmonary disease (COPD) is a condition punctuated by acute exacerbations commonly triggered by viral and/or bacterial infection. Early identification of exacerbation triggers is important to guide appropriate therapy, but currently available tests are slow and imprecise. Volatile organic compounds (VOCs) can be detected in exhaled breath and have the potential to be rapid tissue-specific biomarkers of infection etiology. Objectives: To determine whether volatile organic compound measurement could distinguish viral from bacterial infection in COPD. Methods: We used serial sampling within in vitro and in vivo studies to elucidate the dynamic changes that occur in VOC production during acute respiratory viral infection. Highly sensitive gas chromatography–mass spectrometry techniques were used to measure VOC production from infected airway epithelial-cell cultures and in exhaled breath samples from healthy subjects experimentally challenged with rhinovirus (RV)-A16 and from subjects with COPD with naturally occurring exacerbations. Measurements and Main Results: We identified a novel VOC signature comprising decane and other long-chain alkane compounds that is induced during RV infection of cultured airway epithelial cells and is also increased in the exhaled breath from healthy subjects experimentally challenged with RV and from patients with COPD during naturally occurring viral exacerbations. These compounds correlated with the magnitude of antiviral immune responses, viral burden, and exacerbation severity but were not induced by bacterial infection, suggesting that they represent a specific virus-inducible signature. Conclusions: Our study highlights the potential for measurement of exhaled breath VOCs as rapid, noninvasive biomarkers of viral infection. Further studies are needed to determine whether measurement of these signatures could be used to guide more targeted therapy with antibiotic/antiviral agents for COPD exacerbations.
- 1 November 2021
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 204 (9) , 1075-1085
Virus-induced Volatile Organic Compounds Are Detectable in Exhaled Breath during Pulmonary Infection
Rationale: Chronic obstructive pulmonary disease (COPD) is a condition punctuated by acute exacerbations commonly triggered by viral and/or bacterial infection. Early identification of exacerbation triggers is important to guide appropriate therapy, but currently available tests are slow and imprecise. Volatile organic compounds (VOCs) can be detected in exhaled breath and have the potential to be rapid tissue-specific biomarkers of infection etiology. Objectives: To determine whether volatile organic compound measurement could distinguish viral from bacterial infection in COPD. Methods: We used serial sampling within in vitro and in vivo studies to elucidate the dynamic changes that occur in VOC production during acute respiratory viral infection. Highly sensitive gas chromatography–mass spectrometry techniques were used to measure VOC production from infected airway epithelial-cell cultures and in exhaled breath samples from healthy subjects experimentally challenged with rhinovirus (RV)-A16 and from subjects with COPD with naturally occurring exacerbations. Measurements and Main Results: We identified a novel VOC signature comprising decane and other long-chain alkane compounds that is induced during RV infection of cultured airway epithelial cells and is also increased in the exhaled breath from healthy subjects experimentally challenged with RV and from patients with COPD during naturally occurring viral exacerbations. These compounds correlated with the magnitude of antiviral immune responses, viral burden, and exacerbation severity but were not induced by bacterial infection, suggesting that they represent a specific virus-inducible signature. Conclusions: Our study highlights the potential for measurement of exhaled breath VOCs as rapid, noninvasive biomarkers of viral infection. Further studies are needed to determine whether measurement of these signatures could be used to guide more targeted therapy with antibiotic/antiviral agents for COPD exacerbations.
- Open Access
- 1 September 2020
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 202 (5) , 648-649
A New Role for CXCL4 in Respiratory Syncytial Virus Disease
- 1 September 2020
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 202 (5) , 648-649
Open AccessA New Role for CXCL4 in Respiratory Syncytial Virus Disease